- Home
- ATRA vs PMN Comparison
ATRA vs PMN Comparison
Compare ATRA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | PMN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 34.6M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ATRA | PMN |
|---|---|---|
| Price | $5.42 | $24.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 142.1K | 53.7K |
| Earning Date | 04-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 110.28 |
| EPS | ★ 2.93 | N/A |
| Revenue | ★ $128,940,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.85 | ★ N/A |
| Revenue Growth | ★ 1404.02 | N/A |
| 52 Week Low | $3.92 | $0.29 |
| 52 Week High | $19.15 | $25.00 |
Technical Indicators
Market Signals| Indicator | ATRA | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 73.11 |
| Support Level | $4.06 | $0.43 |
| Resistance Level | $5.71 | N/A |
| Average True Range (ATR) | 0.49 | 2.03 |
| MACD | 0.38 | 0.61 |
| Stochastic Oscillator | 76.14 | 82.58 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.